Nona Biosciences teams with Alaya.bio for CAR-T therapy

Nona Biosciences has entered a partnership with biotech firm Alaya.bio to advance CAR-T cell therapies. This collaboration will leverage Nona's HCAb Harbour Mice platform and site-specific conjugation technology alongside Alaya.bio’s polymeric in situ delivery platform to create new CAR-T product candidates for potential clinical use.

Dr. Jingsong Wang, Chairman of Nona Biosciences, expressed enthusiasm about the collaboration, noting that the combination of Nona’s advanced technology with Alaya.bio’s innovative delivery system could lead to the development of promising CAR-T therapies for patients globally.

Nona’s site-specific conjugation technology, which preserves the antibody’s binding and function, enhances the precision of Alaya.bio’s polymeric delivery systems. The collaboration will proceed in a phased approach. Initially, Nona will provide Alaya.bio with access to antibodies targeting multiple sites for Alaya.bio’s in vivo CAR program.

Alaya.bio will then select specific binders to be conjugated onto their polymeric nanoparticles using Nona’s technology, aiming to push their CAR product candidates toward clinical trials.

Renaud Vaillant, CEO and co-founder of Alaya.bio, expressed excitement over the partnership, highlighting the high quality and efficacy of the targeting agents that will be used. He emphasized that the collaboration has identified promising new-generation candidates that stand out from existing solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!